The Secretary of Health (SOH) approved the HTAC recommendation on the reinclusion of vasopressin in the PNF on 02 March 2022. Link to issuance Vasopressin 20 I.U./mL (I.V./I.M./S.C.) was previously listed in the Philippine National Formulary (PNF); however, it was automatically delisted in 2017 since the drug was no longer registered in the Philippine Food continue reading : Vasopressin 20 I.U./mL (I.V./I.M./S.C.)
Pfizer-BioNTech (10ug/dose) COVID-19 Vaccine for Children 5 to 11 Years Old
Evidence Summary: Document Link
Pertuzumab for HER2+ Breast Cancer
Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Document link: Pertuzumab for HER2+ Breast Cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview:
Sambong 250mg Tablet for Anti-Urolithiasis (Kidney Stones)
SOH approves the HTAC recommendation on the minor inclusion of sambong 250mg tablet in PNF The Secretary of Health approved the HTAC recommendation on the minor inclusion of sambong 250mg tablet for anti-urolithiasis (kidney stones) in the Philippine National Formulary (PNF) on 14 January 2022. Minor inclusions are applicable to drugs that are currently listed in the continue reading : Sambong 250mg Tablet for Anti-Urolithiasis (Kidney Stones)
Use of Casirivimab + Imdevimab for the Treatment of COVID-19
HTAC interim recommendation on the use of casirivimab+imdevimab for the treatment of COVID-19 On 24 December 2021, the Secretary of Health approved and signed the Health Technology Assessment Council (HTAC) interim recommendation for the government not to finance casirivimab+imdevimab for the treatment of COVID-19. The Philippine Food and Drug Administration (FDA) issued an Emergency Use Authorization continue reading : Use of Casirivimab + Imdevimab for the Treatment of COVID-19